Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

home / approval-alert / ciltacabtagene-autoleucel-for-relapsed-refractory-multiple-myeloma

Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

In February 2022, the FDA approved ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy.